Antibody Developability-enhanced Engineering Services

Overview of Antibody Developability-enhanced Engineering

Therapeutic antibodies have revolutionized the treatment of various diseases by targeting specific molecules involved in the disease process. However, their development may be challenging, especially at high concentrations, due to issues like self-association, viscosity, and phase separation. As a result, improving the developability of therapeutic antibodies is of great importance to enhance their efficacy and safety in clinical settings.

Fig. 1 The human IgG antibody's basic structure.¹

Antibody Developability-enhanced Engineering Service at Creative Biolabs

At the early phase of therapeutic antibody development, it is important to enhance their developability for better antibody properties. Based on our expertise and experience in antibody engineering, Creative Biolabs delivers a cost-effective antibody developability-enhanced engineering service to support global customers' significant projects.

Within the engineering process, we are able to enhance and assess the developability profile of your antibody in the initial stages to provide the most effective antibody sequence. Simultaneously, we provide various rapid and high-throughput approaches (i.e. computer-aided molecular design, blotting, flow cytometry.) to screen the optimal antibodies. At Creative Biolabs, our experienced scientists offer customized strategies to minimize risk and enhance the success of your antibody development efforts, ensuring optimal outcomes in clinical settings.

In addition, our service focuses on pharmacokinetic improvement and pharmaceutical property development of therapeutic antibodies, which includes the following:

• Antibody Pharmacokinetic Improvement Service

Enhancing the pharmacokinetics of a therapeutic antibody can lead to reduced dosages, the possibility of developing a subcutaneous formulation, and ultimately lowering the overall cost. The main mechanisms by which therapeutic antibodies are cleared from the body include nonspecific clearance and antigen-binding mediated clearance. According to that, Creative Biolabs delivers a service to improve therapeutic antibodies' pharmacokinetics by reducing the two causes, including:

• Antibody Pharmaceutical Property Development Service

Low thermostability, low solubility, low chemical stability, and high heterogeneity are important inducers that cause low biological activity and easy aggregation of therapeutic antibodies, which greatly improve the immunogenicity of therapeutic antibodies and affect their therapeutic efficacy. Creative Biolabs' antibody pharmaceutical property development service has the potential to act as an effective tool to optimize these properties, thereby improving the chances of successful antibody development for our customers. The following are several strategies we utilize:

Benefits for You

• Competent research team.
• Multiple strategies to satisfy distinctive needs.
• Fast timeline to speed up progress.
• Strict quality control ensures active traceability.
• All-inclusive service.

Frequently Asked Question

Q1: Is it necessary to utilize structure-based design in antibody engineering and evaluate its developability?

A1: Computational antibody design methods have revolutionized therapeutic discovery by offering a cost-effective and efficient solution. Accurate antibody structure models play a crucial role in estimating developability parameters, paired with the growing availability of antibody sequences. This enables large-scale structural antibody virtual screening, making structure-based design essential in antibody engineering and developability assessment.

If you are interested in our antibody developability-enhanced engineering service, please reach out to us with your projects.

Reference

1. Wang, Bo, et al. "Optimization of therapeutic antibodies." Antibody therapeutics 4.1 (2021): 45-54.